Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Down 39.2% in February

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 567,600 shares, a decrease of 39.2% from the February 13th total of 934,300 shares. Approximately 0.8% of the company’s shares are sold short. Based on an average trading volume of 955,300 shares, the days-to-cover ratio is presently 0.6 days.

Tiziana Life Sciences Stock Performance

NASDAQ TLSA traded up $0.09 during trading hours on Friday, hitting $1.57. The company had a trading volume of 375,854 shares, compared to its average volume of 433,491. The business has a 50 day moving average of $0.90 and a 200-day moving average of $0.92. Tiziana Life Sciences has a 1-year low of $0.41 and a 1-year high of $1.91.

Institutional Trading of Tiziana Life Sciences

A number of large investors have recently bought and sold shares of the business. Bison Wealth LLC acquired a new stake in Tiziana Life Sciences during the 4th quarter worth approximately $30,000. Zhang Financial LLC raised its stake in shares of Tiziana Life Sciences by 34.3% during the fourth quarter. Zhang Financial LLC now owns 93,187 shares of the company’s stock worth $65,000 after purchasing an additional 23,800 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Tiziana Life Sciences by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 245,722 shares of the company’s stock worth $171,000 after purchasing an additional 27,041 shares during the period. Finally, Sanctuary Advisors LLC purchased a new position in Tiziana Life Sciences in the 3rd quarter valued at $864,000.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.